Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease-Reference-Cited by-同舟云学术

Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease

Published:2022-12-13 Issue:22 Volume:328 Page:2269
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Etminan Mahyar¹,Rezaeianzadeh Ramin¹,Kezouh Abbas²,Aminzadeh Kevin³

Affiliation:

1. Faculty of Medicine, University of British Columbia, Vancouver, Canada

2. StatExpert Ltd, Laval, Quebec, Canada

3. School of Dentistry, University of Michigan, Ann Arbor

Abstract

This study examines the association of sublingual buprenorphine/naloxone and dental adverse events using the IQVIA health claims database.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2799415/jama_etminan_2022_ld_220067_1670262105.39559.pdf

Reference5 articles.

1. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.;Psaty;JAMA,2010

2. Buprenorphine/naloxone and dental caries: a case report.;Suzuki;Am J Addict,2012

3. Buprenorphine: Drug Safety Communication: FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. News release. US Food and Drug Administration. January 12, 2022. Accessed August 1, 2022. https://www.fda.gov/safety/medical-product-safety-information/buprenorphine-drug-safety-communication-fda-warns-about-dental-problems-buprenorphine-medicines

4. IQVIA PharMetrics Plus factsheet. IQVIA. Published April 8, 2022. Accessed August 1, 2022. https://www.iqvia.com/library/fact-sheets/iqvia-pharmetrics-plus

5. Highlights of prescribing information: SUBOXONE sublingual film. US Food and Drug Administration. December 2011. Accessed August 5, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020733s007s008lbl.pdf

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orally dissolving buprenorphine for opioid use disorder linked to caries;The Journal of the American Dental Association;2024-07

2. Buprenorphine Use for Analgesia in Palliative Care;Pharmacy;2024-05-13

3. Buprenorphine for Pain: A Narrative Review and Practical Applications;The American Journal of Medicine;2024-05

4. Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration;Current Drug Safety;2024-05

5. “It’s My Secret”: Shame as a Barrier to Care in Individuals With Opioid Use Disorder;Journal of the American Psychiatric Nurses Association;2024-04-06